The Targeted Therapy Market Is Projected to Expand at an 8% CAGR, Reaching $157.2 Billion by 2030

Targeted Therapy Market Share

Targeted Therapy Market Analysis

Targeted Therapy Market Report

The Business Research Company’s Targeted Therapy Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, October 13, 2026 /EINPresswire.com/ -- The targeted therapy segment within oncology is experiencing rapid advancement, reflecting broader shifts in pharmaceutical innovation focused on precision medicine. As global healthcare systems adapt to more personalized treatment approaches, targeted therapies are becoming an integral part of cancer care. This overview explores the market size, key players, driving forces, and future directions shaping this specialized field.

Market Size and Outlook for the Targeted Therapy Market
The targeted therapy market is projected to surpass $157 billion by 2030. It forms a significant part of the broader Oncology Drugs sector, which is expected to reach around $441 billion that same year, with targeted therapies accounting for approximately 36% of the total. Within the expansive Pharmaceuticals industry, anticipated to hit $2,496 billion by 2030, targeted therapy will represent close to 6% of the entire market value.

Request A Free Sample Of The Targeted Therapy Market Report
https://thebusinessresearchcompany.com/sample_request?id=27496061&type=smp&name=Targeted%20Therapy%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR

Competitive Landscape in the Targeted Therapy Arena
Globally, the targeted therapy market is shaped by a mix of large pharmaceutical corporations and focused biotechnology firms. These companies emphasize precision medicine, biomarker-driven treatments, novel drug development technologies, and expanding targeted therapy portfolios. Their competition centers on treatment specificity, clinical effectiveness, patient outcomes, personalization, and regulatory approvals. Understanding this ecosystem helps stakeholders pinpoint growth prospects, new product innovations, and partnership opportunities within the evolving precision medicine landscape.

Top Market Shareholder in Targeted Therapy
F. Hoffmann-La Roche Ltd leads globally in targeted therapy sales, ranking first in 2025 with a 3% market share, according to The Business Research Company. The firm’s portfolio includes a wide range of precision medicines designed for cancer treatment, utilizing biomarker-guided therapy selection and tailored healthcare approaches across several therapeutic areas.

Access The Detailed Targeted Therapy Market Report Here
https://thebusinessresearchcompany.com/report/targeted-therapy-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR

Regional Leadership in the Targeted Therapy Market
North America is set to be the dominant region in the targeted therapy market through 2030, reaching $63 billion from $46 billion in 2025, with a compound annual growth rate (CAGR) of 6%. This growth is driven by expanded use of precision oncology, increased availability of biomarker-based diagnostic tests, higher investments in cancer research, and a rising number of regulatory approvals for targeted treatments across various cancer types.

Segment Breakdown and Leading Categories in Targeted Therapy
The targeted therapy market is divided into two primary product types: small molecule medicines and monoclonal antibodies. Monoclonal antibodies are expected to be the largest segment by 2030, accounting for 60% or $94 billion of the total market. This segment benefits from highly selective biologics suited for complex cancers, a preference for treatments with greater target precision and lower systemic side effects, advancements in antibody engineering, and broader availability of antibody therapies for multiple oncology indications.

Additional segmentation includes distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies. Application-wise, the market covers indications like breast cancer, colorectal cancer, leukemia, lung cancer, lymphoma, renal cancer, and other oncological conditions.

Primary Factors Fueling Growth in the Targeted Therapy Market
Three main drivers are expected to propel the targeted therapy market’s expansion through 2030. The first is the increasing prevalence of cancer and chronic diseases. Rising cases of breast, lung, colorectal, prostate, ovarian, melanoma, and hematological cancers are driving demand for treatments that precisely target molecular pathways involved in disease, while minimizing harm to healthy tissues. Improved diagnosis rates, better healthcare accessibility, and personalized oncology approaches are also expanding the patient base. This factor is estimated to contribute about 2.4% growth annually.

The second driver is rapid progress in precision medicine and biomarker testing. Technologies like genomic profiling, next-generation sequencing, liquid biopsy, and companion diagnostics enable physicians to identify actionable mutations and match patients with the most effective therapies. Faster, more accurate tests and increasing biomarker-guided drug approvals are expanding the reach of precision oncology globally. This component is projected to add roughly 2.3% annual market growth.

The third key influence is the growing investment in biopharmaceutical research and drug development. Pharmaceutical companies and biotech firms are intensifying research into monoclonal antibodies, antibody-drug conjugates, tyrosine kinase inhibitors, bispecific antibodies, targeted radiopharmaceuticals, and other next-generation therapies. Strong funding, numerous clinical trials, strategic partnerships, and favorable regulatory environments are accelerating commercialization. This driver is expected to contribute around 2.2% growth yearly.

Competitive Dynamics Within the Targeted Therapy Space
The targeted therapy market exhibits moderate fragmentation, with the top 10 companies accounting for 20% of total revenue in 2025. This reflects considerable challenges related to research complexity, clinical development, biomarker identification, intellectual property, and specialized capabilities. Leading firms maintain market share through diversified targeted portfolios, robust clinical pipelines, extensive healthcare networks, and ongoing investments in precision medicine. As demand for personalized cancer treatments, biomarker-driven care, and improved patient outcomes grows, increased research spending, collaborations, and portfolio expansions will solidify their competitiveness.

Market Shares of Leading Companies in 2025
The major players and their respective market shares in 2025 include:
1. F. Hoffmann-La Roche Ltd – 3%
2. AstraZeneca – 3%
3. Novartis AG – 2%
4. Pfizer Inc – 2%
5. Merck & Co Inc – 2%
6. Bristol Myers Squibb – 2%
7. Daiichi Sankyo Company Limited – 2%
8. Eli Lilly and Company – 1%
9. Johnson & Johnson – 1%
10. Amgen Inc – 1%

Innovation and Market Impact of New Targeted Therapies
Recent targeted therapy approvals are transforming the market by expanding treatment options for defined patient groups, addressing unmet needs, and enhancing the precision of cancer care. For example, in July 2026, Celcuity Inc. received FDA approval for REVTORPYK (Gedatolisib), indicated for HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer. This drug works by inhibiting all class I PI3K isoforms along with mTORC1/mTORC2, targeting the pathway comprehensively and offering a novel treatment avenue for patients whose disease progressed after endocrine therapy.

Strategic Priorities Guiding Companies in Targeted Therapy
Key focuses for companies in this space include:
• Utilizing precision biomarker testing to enhance treatment selection accuracy
• Developing next-generation antibody-drug conjugates to widen targeted cancer therapy options
• Advancing protein degradation technologies for more precise cancer treatments
• Creating bispecific antibodies aimed at improving tumor-specific targeting
• Implementing personalized treatment methods to increase adoption of biomarker-driven therapies

Growth Opportunities and Market Outlook to 2030
Monoclonal antibodies and small molecule medicines present substantial growth potential, with combined market value expected to increase by over $47 billion by 2030. Monoclonal antibodies are projected to contribute $28 billion, while small molecules add $19 billion between 2025 and 2030. This momentum will be fueled by biomarker-specific therapies, combination regimens, innovations in antibody engineering and targeted drug delivery, as well as an expanding number of precision oncology approvals across cancer types.

Commonly Asked Questions About the Targeted Therapy Market
Q: What is the projected compound annual growth rate for the targeted therapy market?
A: The market is expected to grow at a CAGR of 7% through 2030.

Q: Which country will dominate the targeted therapy market?
A: The USA is forecasted to be the largest market, valued at $59 billion in 2030, up from $42 billion in 2025, growing at a 7% CAGR. Growth will be supported by advancements in targeted drug development, widespread use of genomic profiling, increased healthcare expenditure on innovative oncology medicines, and collaboration between biotech firms and research institutions.

Q: Who are the major companies operating in the targeted therapy market?
A: Leading companies include F. Hoffmann-La Roche Ltd, AstraZeneca, Novartis AG, Pfizer Inc, Merck & Co Inc, Bristol Myers Squibb, Daiichi Sankyo Company Limited, Eli Lilly and Company, Johnson & Johnson, Amgen Inc, Sanofi SA, Takeda Pharmaceutical Company Limited, Bayer AG, GlaxoSmithKline plc, Gilead Sciences Inc, Biogen Inc, Arcus Biosciences, Inc., Agenus, Inc, Nektar Therapeutics Inc., Aurinia Pharmaceuticals Inc., and Celdara Medical LLC.

Q: Who supplies the key raw materials for targeted therapy production?
A: Major raw material suppliers include BASF SE, Evonik Industries AG, Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group Ltd, Catalent Inc., Siegfried Holding AG, Wuxi AppTec Co Ltd, Samsung Biologics Co Ltd, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, AGC Biologics, Piramal Pharma Solutions, Curia Global Inc., Cambrex Corporation, CordenPharma, Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd, Zhejiang Huahai Pharmaceutical Co Ltd, and Divi’s Laboratories Limited.

Q: Which wholesalers and distributors play a major role in the targeted therapy market?
A: Significant distributors and wholesalers include Cencora Inc., Cardinal Health Inc., McKesson Corporation, Henry Schein Inc., Morris & Dickson Co LLC, Smith Drug Company, Anda Pharmaceuticals, Capital Wholesale Drug Company, Dakota Drug Inc., Louisiana Wholesale Drug Company, Value Drug Company, FFF Enterprises Inc., Metro Medical Supply Inc., Medline Industries LP, CuraScript Specialty Distribution, Oncology Supply, ASD Healthcare, Besse Medical, BioCare Specialty Distribution, and Medico-Mart Inc.

Q: Who are the primary end users of targeted therapies?
A: Leading end users encompass major cancer and medical centers such as Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Mayo Clinic, Cleveland Clinic, Dana-Farber Cancer Institute, Johns Hopkins Medicine, Mayo Clinic Cancer Center, Stanford Health Care, UCLA Health, Northwestern Medicine, Mount Sinai Health System, NYU Langone Health, Cedars-Sinai Medical Center, City of Hope, Fred Hutchinson Cancer Center, and Massachusetts General Hospital.

Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We have published over 30,000+ reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:
The Business Research Company
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email: marketing@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Oliver Guirdham
The Business Research Company
+44 7882 955267
Visit us on social media:
LinkedIn
Facebook
X